Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin

Herbert L DuPont, Ray A Wolf, Robert J Israel, Mark Pimentel, Herbert L DuPont, Ray A Wolf, Robert J Israel, Mark Pimentel

No abstract available

Keywords: antibiotics; irritable bowel syndrome with diarrhea; resistance; rifaximin; skin swabs; staphylococcal isolates; susceptibility.

References

    1. Salix Pharmaceuticals. 2015. Xifaxan (rifaximin) tablets, for oral use (package insert). Salix Pharmaceuticals, Raleigh, NC.
    1. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, Paterson C, Bortey E, Forbes WP. 13 August 2016. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology doi:10.1053/j.gastro.2016.08.003.
    1. Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Finegold SM, Molitoris D, Vaisanen ML. 2009. Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother 53:1–3. doi:10.1128/AAC.00441-08.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere